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Robich et al Acquired Cardiovascular Diseasepostoperative complications aside from increased need for
blood transfusion. Patients with HIV should not be denied
an indicated cardiovascular surgery just because of their
disease. Optimizing control of HIV preoperatively by
ensuring low viral loads, reasonable immune reconstitution,
and treatment of anemia may also help improve outcomes.
There was a time when discussion of the chronic diseases of
HIV patients was considered unnecessary, but with HAART
therapy that has changed. Patients are living longer and
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Dr Hossein Almassi (Milwaukee, Wis). Nice presentation. This
is a timely presentation, long overdue. I still remember a time
when a member of this association in Wisconsin announced to
the public that he would not operate on HIV-positive patients
needing cardiac operations. Of course, we have come a long
way since then, and a lot of progress has been made as we heard
from Dr Robich in his presentation today.
With HAART therapy, patients survive long with their chronic
disease, and as cardiac surgeons, we are going to see more of this
baby boomer generation with HIV requiring cardiac surgery.
The study is an analysis of a large administrative database over a
10-year period. It provides some important information; although,
it suffers from the lack of patient level data, and you have admitted
that in your manuscript. Information such as the stage of the HIV,
the level and the length of the antiretroviral therapy, indications for
surgery, urgency of the operation, and some other information are
lacking.
The patients with HIV were younger than the non-HIV group
with a higher rate of renal failure and liver disease but with no
increase in renal complications postoperatively, but I will get to
that later on.
And as you mentioned, CABG was the predominant operation
in close to 40% of the patients. In propensity-matched patients,
HIV-positive status had no impact on in-hospital mortality, but
postoperative complications and the need for blood transfusions
were significantly higher in this cohort of patients, yet there was
no difference in costs between the 2 groups. That is interesting
to see.
Dr Robich, I have 3 questions. I am going to ask you 1 at a time.
Preoperative renal failure was a risk factor for mortality in
HIV-positive patients, but the rate of postoperative renal failurediovascular Surgery c Volume 148, Number 6 3073
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patients.
Was the high rate of renal failure preoperatively distributed
evenly throughout the study period, or was it more concentrated
in the earlier period of this study? And if so, did you notice a
difference between the outcomes of patients in the earlier part of
this study versus the latter part of this study?
Dr Robich. That is a very good question. Thank you,
Dr Almassi, for reading our manuscript and discussing our talk.
To answer the first question, the rates of renal failurewere pretty
steady throughout the study period. We did not see any large
increase in renal failure over the course of the study period.
Dr Almassi. Could you tell us why patients with HIV require
more blood transfusions, and you alluded to it that they did. I noted
in your slides that the postoperative anemia was more prevalent in
HIV-positive patients.
What would happen if you did a separate analysis excluding
the anemic patients? Would the difference for the increase in
transfusion rate still be significant, and if so, could you elaborate
on the reasons for this increased need for blood transfusion in these
patients?
DrRobich. That is an excellent question. So the level of anemia
we think is probably due in some part obviously to their HIV.
We did not do that analysis of looking at it without the blood
transfusion. But my suspicion is, if we did do that, that the
significant increase that we saw in any complication rates would
no longer be there.
And then the other part of your question was regarding whether
or not..
Dr Almassi.. you should do a separate analysis excluding the
anemic patients, preoperative anemia. Would still the difference in
transfusion be significant?
Dr Robich. Right. That is a good question. We did not look
at that either, and I actually do not know the answer to that. I am
not sure if it would or not. I assume it would, but I do not know.
Dr Almassi. My last question is regarding the complication
rate. I think you partially answered that; that it was higher in
HIV-positive patients. It was interesting that it was increasing
throughout the study period over the 10 years.
Did you look at the components of these morbidities to see what
the predominant contributors other than anemia are? Because I
think that is important information for treating physicians to figure
out what to do with those factors so that the complication rate will
drop down because clearly the mortality has dropped, but the
complication rate is going in the opposite direction.
Dr Robich. That is exactly right.
Dr Almassi. Nice presentation. I enjoyed your presentation.
Dr Robich. Thank you very much.
So to answer your question, I think 1 of the things that. I am
sorry, I lost my train of thought. Your question again was
regarding?
Dr Almassi. Components of the morbidities other than anemia.
Dr Robich. Oh, right. I am sorry.
Dr Almassi. Have you looked at the components of morbidity
to see what they are, the significant contributors of this
increasing rate of morbidities so that then surgeons and physicians
can deal with it and to come up with strategies to take care of
those?3074 The Journal of Thoracic and Cardiovascular SurDrRobich.Right. I think 1 of the reasons that we saw increased
complication rates and lower mortality is that there probably were
patients in the past who were dying, and because of better care, we
were able to rescue them from death. And, unfortunately, they
probably suffered more complications as they may have died
before, but now they have a complication. That is 1 reason.
The second thing that is interesting is there are several
modifiable risk factors that I did not present today but that we
have noticed and that would be important. One of the things that
we found would be the coagulopathy. I think if we address that
and if we maximize the therapy for their HIVand address any fluid
and electrolyte imbalances, those were all risk factors as well for
complications.
So I think there are modifiable risk factors we can address to
further improve outcomes.
Dr Charles M. Geller (New York, NY). Thank you for this
thought-provoking presentation. Having had the opportunity to
operate on many HIV-positive patients each year for the past 2
decades, I believe that all immunodeficient patients are not alike.
Were you able to determine either a viral load level or a
CD4/T-cell count cutoff level at which outcomes in this patient
population were affected?
Dr Robich. That is an excellent question and I think a critical
thing to understand. Unfortunately, this database does not have
that type of clinical data in it, so we do not know what their
CD4 status was. But I think that is an important point.
Dr Mark S. Slaughter (Louisville, Ky). Along those same
lines, there is a difference between being HIV-positive and having
AIDS, so your risk of other, which was essentially open pericardial
windows and cancer, are those just surrogate markers for patients
who have systemic disease and significant immunosuppression?
Dr Robich. That is an excellent point. That is our belief that
these patients are probably a lot more advanced in their disease,
may not have had adequate medical treatment beforehand, and I
would agree with that.
Dr Slaughter. Lastly, you made the comment that there were
fewer strokes, and you believed this was due to the immunomodu-
lation. Predominantly and particularly in coronary surgery, it is an
embolic event related to the atherosclerotic load.
So what immunomodulating effect decreases the atheroscle-
rotic load in these patients?
Dr Robich. Well, that is a good question as well, and I do not
know if it is completely due to the immunomodulation or
decreasing inflammation in general.
And also, as I pointed out, they had less peripheral arterial
disease, and it may be just a factor of them being younger and
not having developed a heavy atherosclerotic burden at this point.
Dr Giuseppe D’Ancona (Palermo, Italy). You mention valve
operations. I was wondering, do you have any specific data about
HIV-positive patients who are drug addicts and the recurrence of
endocarditis or infection because I would presume that then the re-
sults are somewhat different.
Dr Robich. Well, that is true. And about 6% of the patients in
our study over the entire period had endocarditis. However, we
did not look at them separately, endocarditis versus nonendocardi-
tis valve operations, but certainly that would likely have an impact.
Dr Edward G. Soltesz (Cleveland, Ohio). So when we did this
analysis, we actually did the analysis with smaller subgroups asgery c December 2014
Robich et al Acquired Cardiovascular Diseasewell. We did subgroup analysis of only doing CABG, isolated
CABG, isolated valve aortic surgery only, thoracic aortic surgery.
We get a smaller number obviously, but the outcomes are exactly
the same.
We included the larger group practice, including those other
cardiovascular surgeries, mainly open pericardial drainages,
because that is sort of our practice in our entire department. And
we figured because we are going to see them, these types of
patients, we want to sort of know what their outcomes are going
to be in general.
The second issue is to comment on the stroke. So it is very
interesting. In HIV patients as a whole, the incidence of
ischemic stroke and hemorrhagic stroke is increasing, but theThe Journal of Thoracic and Carincidence of atrial fibrillation is lower. So you could potentially
make the connection that these patients, although we cannot
necessarily determine this from this database, that they have less
postoperative atrial fibrillation, and as you said, less embolic
events.
Dr Frank W. Sellke (Providence, RI). I think another way to
look at that is people with HIV may have less of an inflammatory
response, and with the same atherosclerotic burden or emboli, you
do not have the inflammatory influence to propagate the stroke.
And the same thing with atrial fibrillation. You have less
inflammation, so you may have less atrial fibrillation because of
that reason.
Dr Robich. I would agree with that, Dr Sellke.diovascular Surgery c Volume 148, Number 6 3075
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